Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
- Haematologica, Jun 06 2024, | https://doi.org/10.3324/haematol.2024.285534